News & Videos - REALM THERAPEUTICS ORD 10P

Realm Therapeutics Announces Results of 2018 Annual General Meeting PR Newswire MALVERN, Pa., June 14, 2018 MALVERN, Pa. , June 14, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM) a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that all Resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today. Proxy figures will be displayed shortly on the Company's website at...

Realm Therapeutics to Present at June Investor Conferences PR Newswire MALVERN, Pa., May 31, 2018 MALVERN, Pa. , May 31, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company will participate in the following investor conferences in June: The 2018 BIO International Convention presentation on Wednesday, June 6, 2018 at 3:00 p.m. ET at the Boston...

Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis Company Further Strengthens IP Portfolio with New USPTO Notice of Allowance Reiterates Plans to File an Initial New Drug (IND) Application for PR022 in Psoriasis in Q1'19 PR Newswire MALVERN, Pa., May 24, 2018 MALVERN, Pa. , May 24, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today...

Realm Therapeutics Publicly Files Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares PR Newswire MALVERN, Pa., May 23, 2018 MALVERN, Pa. , May 23, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM) (the Company or Realm), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces it publicly filed a registration statement with the United States Securities and Exchange...

Realm Therapeutics Presents Data Highlighting its Proprietary Immunomodulatory Technology's Potential in Acne and Psoriasis at IID 2018 PR Newswire MALVERN, Pa., May 21, 2018 MALVERN, Pa. , May 21, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company presented a poster at the 2018 International Investigative Dermatology (IID) Meeting in Orlando,...

Realm Therapeutics Files Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares PR Newswire MALVERN, Pa., May 2, 2018 MALVERN, Pa. , May 2, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM) (the Company), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces it has confidentially submitted a registration statement to the United States Securities and Exchange...

Realm Therapeutics plc ("Realm Therapeutics", "Realm", or the "Company") Notice of Full Year 2017 Results PR Newswire MALVERN, Pa., April 26, 2018 MALVERN, Pa. , April 26, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company expects to release its results for the year ended December 31, 2017 on May 2, 2018 . A conference call and live audio webcast...

Realm Therapeutics Provides Clinical Update, including Results from a Phase 2 Study of PR013 in Allergic Conjunctivitis PR Newswire MALVERN, Pa., March 12, 2018 MALVERN, Pa. , March 12, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today provides an update on the Company's clinical programs. The Company reports that its Phase 2 study of PR013, a topical ophthalmic solution...

Realm Therapeutics Strengthens its Patent Portfolio with Two New USPTO Notice of Allowances PR Newswire MALVERN, Pa., Feb. 27, 2018 MALVERN, Pa. , Feb. 27, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued notices of allowance for two new patents that expand the intellectual property portfolio...

Realm Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference PR Newswire MALVERN, Pa., Feb. 20, 2018 MALVERN, Pa. , Feb. 20, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announced today that Alex Martin , CEO, will be presenting at the RBC Capital Markets 2018 Global Healthcare Conference, on Thursday, February 22, 2018 at 8:00 a.m. ET at the...

Realm Therapeutics Highlights Strong 2017 Performance and Outlines 2018 Milestones Phase 2 Allergic Conjunctivitis Study Ahead of Schedule; Top-Line Results Anticipated by End of Q1 Phase 2 Atopic Dermatitis Study on Track with Top-Line Results Expected in Late Q3 Year-end 2017 Cash, Cash Equivalents and Short-term Investments Were $33.9 Million PR Newswire MALVERN, Pa., Feb. 15, 2018 MALVERN, Pa. , Feb. 15, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM:RLM), a clinical stage...

Realm Therapeutics to Present at the 5th Annual Dermatology Summit PR Newswire MALVERN, Pa., Jan. 2, 2018 MALVERN, Pa. , Jan. 2, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin , CEO, will be presenting at the 5 th Annual Dermatology Summit, an Advancing Innovation in Dermatology conference, on Sunday, January 7, 2018 at 2:15 p.m. PT at the...

Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR013 for the Treatment of Allergic Conjunctivitis PR Newswire MALVERN, Pa., Dec. 12, 2017 MALVERN, Pa. , Dec. 12, 2017 /PRNewswire/ -- Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announces the first patient has been dosed in its Phase 2 study of PR013, the Company's topical ophthalmic formulation of high concentration...

Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR022 for the Treatment of Atopic Dermatitis PR Newswire MALVERN, Pa., Dec. 5, 2017 MALVERN, Pa. , Dec. 5, 2017 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announced the first patient has been dosed in its Phase 2 study of PR022, the Company's proprietary topical gel formulation of high concentration...

Realm Therapeutics Announces Publication of Positive Preclinical Data on PR022 in the Treatment of Atopic Dermatitis In Vivo and In Vitro Data Demonstrate Reduced Itch and Inflammation Progressing to Phase 2 trial in coming weeks PR Newswire MALVERN, Pa., Nov. 21, 2017 MALVERN, Pa. , Nov. 21, 2017 /PRNewswire/ -- Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announced the publication of...

Realm Therapeutics Appoints Sandy Zweifach as Non-Executive Director and Non-Executive Directors Matthew Hammond and Daniel Hegglin Retire from the Board PR Newswire MALVERN, Pa., Nov. 17, 2017 MALVERN, Pa. , Nov. 17, 2017 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Sanford (Sandy) Zweifach has been appointed to the Company's board as a Non-Executive...

Realm Therapeutics to Present at BIO-Europe® 2017 PR Newswire MALVERN, Pa., Nov. 2, 2017 MALVERN, Pa. , Nov. 2, 2017 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin , CEO, will be presenting at the 23 rd annual BIO-Europe ® , a global life sciences partnering event, on Wednesday, November 8, 2017 at 12:15 p.m. CET at the CityCube Berlin in...

Realm Therapeutics Presents Data Highlighting PR013's Efficacy Reducing Hyperemia and Pruritus Associated with Allergic Conjunctivitis at The American College of Allergy, Asthma, and Immunology (ACAAI) Scientific Meeting PR Newswire MALVERN, Pa., Oct. 30, 2017 MALVERN, Pa. , Oct. 30, 2017 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announced the Company presented data for...